Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-AEGIS
2011-001858-28Phase 3Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Jun 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin, paclitaxel, cisplatin, epirubicin, capecitabine and 4 more in adenocarcinoma of the lower esophagus and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Cancer Trials Ireland. Primary endpoint: Overall survival. Started Jun 2011; status: completed.
02
Drugs
carboplatinpaclitaxelcisplatinepirubicincapecitabine
03
Conditions
adenocarcinoma of the lower esophagusgastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2011-001858-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001858-28.